The stock market marked its biggest decline in nearly a month after Wall Street shed highflying technology stocks. The S&P 500 dropped 1.2%. The Nasdaq Composite slid 2%. Both marked their biggest ...

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

"Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn" was originally created and published by Pharmaceutical ...

Kimberly-Clark plans to acquire Kenvue in a $48.7 billion deal, aiming to boost long-term growth and synergies. Learn more ...

Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling ...

Under the agreement, each Kenvue Inc. (NYSE:KVUE) shareholder would receive $3.5 per share in cash as well as 0.14625 ...

The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...